. 2014 Nov 29;54(12):958–965. doi: 10.2176/nmc.ra.2014-0239

Table 1.

Summary of current medical treatment for functioning pituitary adenoma

	Treatment	Agent	Disadvantage	Remission rate
Prolactinoma	DA	Cabergoline	Cardiac valve insufficiency ^*	70–90% ^10, 12)
Prolactinoma	DA	Bromocriptine	Nausea Orthostatic hypotension Nasal stiffness	70–90% ^10, 12)
Acromegaly	DA	Cabergoline	Same as above	10–40% ²⁷⁾
	DA	Bromocriptine	Same as above	10–40% ²⁷⁾
	SSA	Octreotide Octreotide LAR Lanreotide Autogel	Expensive Nausea Abdominal discomfort Diarrhea Cholelithiasis Insulin inhibition	40–60% ³²⁾
	GRA	Pegvisomant	Liver damage Lipohypertrophy at injection sites	60–90% ^40, 43)
Cushing's disease
Pituitary-directed	DA	Cabergoline	Same as above
Pituitary-directed	SSA	Octreotide LAR	Same as above
Adrenal-directed	AEI	Metyrapone	Adrenal insufficiency	20–70% ^56, 57)
Adrenal-directed	AEI	Mitotane	Irrevesible adrenal change

*: obseved in patients taking greater than 3 mg cabergoline daily. ¹⁷⁾ AEI: adrenal enzyme inhibitor, DA: dopamine agonist, GRA: growth hormone receptor antagonist, SSA: somatostatin analog.